Surg Oncol Clin N Am 16 (2007) 465 469 Index Note: Page numbers of article titles are in boldface type. A Adjuvant therapy, preoperative for gastric cancer, staging and, 339 B Breast cancer, metabolic imaging with 18 F-FDG PET and PET/CT, 277 279 optical tomography with ultrasound localization for diagnosis and treatment monitoring, pre- and postoperative imaging for staging, 447 463 assessing nodal status, 454 comparison of imaging techniques, 453 454 for specific tumor types, 454 457 ductal carcinoma in situ, 454 455 invasive cancer, 455 456 synchronous bilateral disease, 457 for staging and follow-up, 457 459 450 453 mammography, 448 449 453 ultrasonography, 449 450 Bronchoscopy, virtual. See Virtual bronchoscopy. C Calcitonin, serum, in well-differentiated thyroid cancer, imaging studies and, 438 Chest radiography, in patients with melanoma, 408 409 Cholangiocarcinoma, hilar, imaging in diagnosis and staging of, computed tomography, 358 358 ultrasonography, 357 intrahepatic, imaging in diagnosis and staging of, computed tomography, 351 352 352 353 ultrasonography, 352 353 Colon cancer, primary, imaging of, 372 373 Colorectal cancer, imaging for, 369 388 after neoadjuvant chemoradiation, 380 382 distant metastatic disease, 377 380 locally recurrent cancer, 383 384 postoperative imaging and surveillance, 382 383 primary lesion and locoregional disease, 371 377 rationale for preoperative imaging, 369 371 metabolic imaging with 18 F-FDG PET and PET/CT, 280 281 Computed tomography (CT), FDG-PET/ CT scans in thyroid cancer, 442 443 gallbladder cancer, 361 363 346 347 358 351 352 imaging studies in, 409 411 metabolic imaging with combined positron emission tomography (PET)/CT scanners, 273 292 1055-3207/07/$ - see front matter Ó 2007 Elsevier Inc. All rights reserved. doi:10.1016/s1055-3207(07)00055-5 surgonc.theclinics.com
466 INDEX Computed (continued ) with, 331 332 vs. MRI for surgical planning in soft tissue sarcomas, 392 394, 398 399 D Drug delivery, nanovectors for, 300 303 Ductal carcinoma in situ, imaging modalities for, 454 455 E Edema, peritumoral, imaging of, in extremity soft tissue sarcoma, 395 Endoscopic ultrasound, preoperative staging of gastric cancer with, 332 334 Esophageal cancer, metabolic imaging with 18 F-FDG PET and PET/CT, 279 280 Extremity soft tissue sarcoma. See Sarcomas. G Gallbladder cancer, imaging in diagnosis and staging of, 358 364 computed tomography, 361 363 363 363 364 ultrasonography, 359 361 Gastric cancer, preoperative staging and postoperative surveillance for, 329 342 postoperative surveillance, 339 340 preoperative considerations, 330 331 preoperative staging recommendations, 337 339 specific imaging studies, 331 337 staging and preoperative adjuvant therapy, 339 H Head and neck cancers, metabolic imaging with 18 F-FDG PET and PET/CT, 281 Hepatobiliary malignancies, use of imaging, 343 368 gallbladder cancer, 358 364 Hepatocellular carcinoma, use of imaging in diagnosis and staging of, computed tomography, 346 347 347 348 348 349 ultrasonography, 345 346 Hilar cholangiocarcinoma, imaging in diagnosis and staging of, computed tomography, 358 358 ultrasonography, 357 Histologic grade, imaging and, in soft tissue sarcoma, 394 395 Hybrid imaging technology, optical tomography with ultrasound localization for breast cancer, I Imaging, in surgical oncology, 273 463 breast cancer, in pre- and postoperative staging, 447 463 optical tomography with ultrasound localization, colorectal cancer, 369 388 after neoadjuvant chemoradiation, 380 382 distant metastatic disease, 377 380 locally recurrent cancer, 383 384 postoperative imaging and surveillance, 382 383 primary lesion and locoregional disease, 371 377 rationale for preoperative imaging, 369 371 gastric cancer, 329 342 postoperative surveillance, 339 340 preoperative considerations, 330 331 preoperative staging recommendations, 337 339
INDEX 467 specific imaging studies, 331 337 staging and preoperative adjuvant therapy, 339 343 368 gallbladder cancer, 358 364 intrahepatic cholangiocarcinoma, melanoma, 403 430 evidence-based review of imaging studies in, 408 425 National Comprehensive Cancer Network guidelines for, 404 408 metabolic imaging, 273 292 current clinical role of, 275 286 next generation of tracers for, 286 287 positron emission tomography/ct scanning principles and techniques, 274 275 nanotechnology for sensing, imaging, and treating cancer, 293 305 soft tissue sarcoma, 389 402 difficulties in management of, 390 surgery and radiation for, 390 thyroid cancer, 431 445 in long-term management, 436 443 preoperative assessment, 431 436 virtual bronchoscopy, 323 328 clinical application, 325 327 technical considerations, 325 Intrahepatic cholangiocarcinoma, imaging, computed tomography, 351 352 352 353 ultrasonography, 352 353 Invasive breast cancer, imaging modalities for, 455 456 with extensive ductal carcinoma in situ, 456 Iodine 131. See Radioactive iodine. L Laparoscopic exploration, preoperative staging of gastric cancer with, 336 337 Lung cancer, metabolic imaging with 18 F-FDG PET and PET/CT, 275 276 virtual bronchoscopy in, 323 328 Lymphoma, metabolic imaging with 18 F-FDG PET and PET/CT, 283 Lymphoscintigraphy, preoperative and intraoperative, in patients with melanoma, 413 415 M Magnetic resonance imaging (MRI), detection and staging of breast cancer, 450 453 gallbladder cancer, 363 347 348 352 in patients with melanoma, review of imaging studies in, 411 413 with, 334 335 vs. CT for surgical planning in soft tissue sarcomas, 392 394, 398 399 Mammography, 448 449 Markers, serum tumor, in thyroid cancer, imaging studies and, 437 438 Melanoma, imaging studies in patients with, 403 430 evidence-based review of, 408 425 National Comprehensive Cancer Network guidelines for, 404 408 and PET/CT, 276 277
468 INDEX Metabolic imaging, in surgical oncology, 273 292 combined PET/CT scanning principles and techniques, 274 275 current clinical role of 18 F-FDG PET and PET/CT, 275 286 breast cancer, 277 279 colorectal cancer, 280 281 esophageal cancer, 279 280 head and neck cancers, 281 lung cancer, 275 276 lymphoma, 283 melanoma, 276 277 renal cell carcinoma, 286 sarcomas, 283 285 thyroid cancer, 281 283 next generation of tracers for, 286 287 Metastatic disease, distant, from colorectal cancer, imaging of, 377 380 melanoma in sentinel lymph nodes, conventional imaging of, 414 416 N Nanotechnology, for sensing, imaging, and treating cancer, 293 305 National Comprehensive Cancer Network, guidelines for imaging studies in melanoma, 404 408 evaluation of recurrent disease, 407 408 follow-up, 407 staging, 404 407 Nodal status, assessment of, in breast cancer patients, 454 O Optical tomography, with ultrasound localization for breast cancer diagnosis and treatment monitoring, P Positron emission tomography (PET), detection and staging of breast cancer, 453 FDG-PET/CT scans in thyroid cancer, 442 443 gallbladder cancer, 363 364 348 349 358 imaging studies in, 420 425 PET/CT scanning, 424 425 and combined PET/CT scanners, 273 292 current clinical role of, 275 286 next generation of, 286 287 principles and novel scanning techniques, 274 275 with, 335 336 Postoperative imaging, of soft tissue sarcoma, 395 396, 399 R Radioactive iodine, for well-differentiated thyroid cancer, 438 440 side effects, 441 442 preoperative imaging of thyroid nodules, 435 436 Rectal cancer, imaging after neoadjuvant chemotherapy, 380 381 locally recurrent, imaging of, 383 384 primary, imaging of, 373 377 Remnant ablation, in thyroid cancer, 440 Renal cell carcinoma, metabolic imaging with 18 F-FDG PET and PET/CT, 286 Retroperitoneal sarcoma. See Sarcomas. S Sarcomas, metabolic imaging with 18 F-FDG PET and PET/CT, 283 285 soft tissue, preoperative and postoperative imaging for staging, 389 402 difficulties in management of, 390 surgery and radiation for, 390 Scintigraphy, whole body, in thyroid cancer, 440 441 Serum tumor markers, in thyroid cancer, imaging studies and, 437 438 Soft tissue sarcoma, preoperative and postoperative imaging for staging, 389 402 difficulties in management of, 390
INDEX 469 Soft (continued ) surgery and radiation for, 390 Staging, breast cancer, imaging modalities for, 457 459 Staging, preoperative, of gastric cancer, 329 342 considerations in, 330 331 preoperative adjuvant therapy and, 339 recommendations for, 337 339 specific imaging studies, 331 337 of 343 368 gallbladder cancer, 358 364 of soft tissue sarcoma, 389 402 Surveillance, postoperative imaging and, for colorectal cancer, 382 383 T Thyroglobulin, serum, in well-differentiated thyroid cancer, imaging studies and, 437 438 Thyroid cancer, imaging of, 431 445 in long-term management, 436 443 FDG-PET/CT scanning, 442 443 radioactive iodine for well-differentiated, 438 439 remnant ablation, 440 serum tumor markers, 437 438 side effects to iodine 131 therapy, 441 442 ultrasonography, 437 whole body scintigraphy, 440 441 preoperative assessment, 431 436 alternative studies, 434 436 clinical evaluation, 431 432 ultrasonography, 432 433 and PET/CT, 281 282 U Ultrasonography, detection and staging of breast cancer, 449 450 gallbladder cancer, 359 361 345 346 357 352 353 in long-term management of thyroid cancer, 437 imaging studies in, 416 420 in preoperative evaluation of thyroid nodules, 432 434 Ultrasound localization, optical tomography with, for breast cancer diagnosis and treatment monitoring, V Virtual bronchoscopy, in surgical oncology, 323 328 clinical application, 325 327 technical considerations, 325